Rectal Cancer Rates Are Rising in Young Individuals

PHILADELPHIA (August 23, 2010) –A new analysis has found that while colon cancer rates have remained steady over the past several decades among people under the age of 40, rectal cancer rates are increasing in this population across races and in both sexes. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to diagnose rectal cancer in young individuals who show potential signs of the disease.

Rectal cancer is considered to be rare among young individuals in the United States. Because underestimating rectal cancer’s incidence may lead to missed or delayed diagnoses in younger people, Joshua Meyer, MD, a radiation oncologist currently at Fox Chase Cancer Center, led a team that analyzed trends in rectal cancer incidence in the United States compared with colon cancer trends.  Dr. Meyer worked on this research while at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

By conducting a retrospective study using data from the Surveillance Epidemiology and End Results (SEER) cancer registry, the investigators identified 7,661 colon and rectal cancer patients under age 40 years between 1973 and 2005. The researchers then calculated the change in incidence over time for colon and rectal cancers.

Overall rates of colon and of rectal cancer were low during the years of the study (1.11 cases and 0.42 cases per 100,000, respectively). While colon cancer rates remained essentially flat in individuals under age 40 years in recent decades, rectal cancer rates have been increasing since 1984. Specifically, between 1984 and 2005, the rate of rectal cancer diagnosis rose 3.8% per year.

“We suggest that in young people presenting with rectal bleeding or other common signs of rectal cancer, endoscopic evaluation should be considered in order to rule out a malignancy,” said Dr. Meyer. “This is in contrast to what is frequently done, which is to attribute these findings to hemorrhoids. More frequent endoscopic evaluation may be able to decrease the documented delay in diagnosis among young people,” he explained. Because the overall incidence of rectal cancer is relatively low, the authors do not advocate for a change in screening guidelines.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427